MDCO - The Medicines Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.18
+0.47 (+1.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close32.71
Open33.21
Bid0.00 x 2200
Ask0.00 x 1300
Day's Range32.79 - 33.36
52 Week Range16.69 - 41.33
Volume780,077
Avg. Volume1,549,117
Market Cap2.633B
Beta (3Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-2.96
Earnings DateNov 6, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est56.71
Trade prices are not sourced from all markets
  • Are Options Traders Betting on a Big Move in Medicines Company (MDCO) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Medicines Company (MDCO) Stock?

    Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.

  • Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates
    Zacks

    Alnylam's (ALNY) Q2 Earnings and Revenues Miss Estimates

    Alnylam (ALNY) incurs wider-than-expected loss and misses sales estimates in the second quarter of 2019.

  • Is a Beat in Store for Melinta (MLNT) This Earnings Season?
    Zacks

    Is a Beat in Store for Melinta (MLNT) This Earnings Season?

    Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.

  • Thomson Reuters StreetEvents

    Edited Transcript of MDCO earnings conference call or presentation 24-Jul-19 12:30pm GMT

    Q2 2019 Medicines Co Earnings Call

  • Biotech Firm Wins Over Wall Street With Hopes for New Heart Drug
    Bloomberg

    Biotech Firm Wins Over Wall Street With Hopes for New Heart Drug

    (Bloomberg) -- Medicines Co. is nearing the finish line in its journey to introduce a new type of cholesterol medicine that analysts expect to top $4 billion a year in sales.A trio of late-stage studies over the next few months will show investors whether that target is achievable. The medicine, a twice-a-year injection called inclisiran, was designed as an add-on to statin therapy for high-risk patients who need something more powerful to reduce their LDL cholesterol. Medicines Co. estimates that at least 12.7 million patients in the U.S. could benefit.“There is a genuine belief in the value proposition and what this drug can bring,” chief executive Mark Timney said in an interview at the company’s Parsippany, New Jersey, headquarters. “Being able to lower LDL on top of existing therapies while at the same time giving you that guaranteed adherence” with twice-yearly dosing. Two-thirds of cholesterol patients now stop taking their drugs after a year, he said.Inclisiran’s use with other approved therapies could make Medicines Co. a prime takeout target for companies with cholesterol drugs that are looking to beef up their offerings.“It’s a logical bolt-on for these mega-caps that need assets that have struggled with innovation and filling their pipelines,” Chardan Capital Markets analyst Gbola Amusa said in an interview. “MedCo gives them that shiny new product that makes them look great.” He gave Eli Lilly & Co. and Pfizer Inc. as examples before Pfizer agreed to combine its old blockbusters with generic drugmaker Mylan NV.All 14 analysts following Medicines Co. recommend investors buy shares of the company. The average 12-month price target of $61 implies more than 60% upside from the stock’s last closing price. The company’s market value has already doubled since early January to $2.9 billion.While Wall Street has swooned over the prospect of a blockbuster heart drug and a potential multibillion-dollar deal, there are still skeptics. The stock’s short interest remains elevated, with 30% of shares available for trading sold short, according to financial analytics firm S3 Partners. However, some short sellers covered their positions this month with short bets declining by more than 1.6 million, S3’s Ihor Dusaniwsky said in an email.Medicines Co.’s $950 million in convertible debt could be attracting short-sellers but the stock also has a strong institutional following, according to Timney. Roughly 80% of the company’s shares are held by its ten largest holders, data compiled by Bloomberg show.“We’ve seen an increased investment from existing investors, and what we’ve seen is a lot of new investors are coming in or wanting to,” Timney said. “That was highlighted” by Medicines Co. raising about $150 million through an equity offering at the end of June. That will fund the drugmaker through the second-half of next year and cover its planned regulatory filings.“The last two quarters of this year will be critical as we approach filing for the U.S. and next year filing for Europe,” Timney said.To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Morwenna ConiamFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View
    Zacks

    Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View

    The Medicines Company (MDCO) posts narrower-than-expected loss in Q2. The company did not generate any revenues in the period while its focus is steady on its sole pipeline candidate, inclisiran.

  • Medicines Co (MDCO) Q2 2019 Earnings Call Transcript
    Motley Fool

    Medicines Co (MDCO) Q2 2019 Earnings Call Transcript

    MDCO earnings call for the period ending June 30, 2019.

  • Medicines Co. (MDCO) Reports Q2 Loss, Lags Revenue Estimates
    Zacks

    Medicines Co. (MDCO) Reports Q2 Loss, Lags Revenue Estimates

    Medicines Co. (MDCO) delivered earnings and revenue surprises of 4.55% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    The Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development Program

    - Sequential release of topline pivotal Phase 3 data readouts expected to start in second half of the third quarter

  • ACCESSWIRE

    The Medicines Co. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 24, 2019 / The Medicines Co. (NASDAQ: MDCO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 24, 2019 at 8:30 AM Eastern ...

  • Are Insiders Buying The Medicines Company (NASDAQ:MDCO) Stock?
    Simply Wall St.

    Are Insiders Buying The Medicines Company (NASDAQ:MDCO) Stock?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • GuruFocus.com

    David Einhorn's Greenlight Buys NeuBase Therapeutics Stake

    Shares have dropped 7% Wednesday Continue reading...

  • Melinta (MLNT) Announces Preliminary Product Sales for Q2
    Zacks

    Melinta (MLNT) Announces Preliminary Product Sales for Q2

    Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.

  • Business Wire

    The Medicines Company to Announce Second Quarter 2019 Financial Results on July 24

    The Medicines Company will host a conference call and audio webcast on Wednesday, July 24, 2019 at 8:30 a.m. EDT to discuss its second quarter 2019 financial results and operational developments.

  • MoneyShow

    The Medicines Company MDCO- 2019 Top Picks' Mid-Year Update

    John McCamant, editor of The Medical Technology Stock Letter, chose The Medicines Co. (MDCO) as his top speculative idea for 2019. The stock has since risen 90%. Here's his latest update on this biotechnology play.

  • Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran
    Zacks

    Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran

    Alnylam (ALNY) submits Marketing Authorization Application to the EMA for givosiran in development for the treatment of acute hepatic porphyria.

  • Benzinga

    Notable Insider Buys This Past Week: AbbVie, MGM and More

    Health care companies featured prominently in the week's insider purchases. MGM Resorts International (NYSE: MGM) had a director continue to make indirect share purchases this past week. MGM stock rose about 2% in the past week, while the S&P 500 was essentially flat.

  • Benzinga

    The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 25) ArQule, Inc. (NASDAQ: ARQL ) Zai Lab Ltd (NASDAQ: ZLAB ...

  • Business Wire

    The Medicines Company Announces Pricing of Public Offering of Common Stock

    The Medicines Company (MDCO) (the “Company”) today announced the pricing of a public offering of 4,545,455 shares of its common stock at a public offering price of $33.00 per share. Gross proceeds of the offering are expected to be approximately $150 million, before underwriting discounts and commissions and other transaction expenses. In addition, the underwriters have been granted a 30-day option to purchase from the Company up to an additional 681,818 shares of common stock.

  • Benzinga

    The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...

  • Business Wire

    The Medicines Company Announces Launch of Public Offering of Common Stock

    The Medicines Company (MDCO) (the “Company”) today announced the launch of a public offering of $150.0 million of shares of its common stock. In addition, the underwriters will be granted a 30-day option to purchase from the Company up to an additional $22.5 million of shares of common stock. The Company expects to use the net proceeds of the offering to fund its development of inclisiran and for general corporate purposes.

  • Alnylam Completes Enrollment in Phase III Study of Lumasiran
    Zacks

    Alnylam Completes Enrollment in Phase III Study of Lumasiran

    Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.

  • Markit

    See what the IHS Markit Score report has to say about Medicines Co.

    Medicines Co NASDAQ/NGS:MDCOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for MDCO with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MDCO. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MDCO are favorable, with net inflows of $2.28 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Did Hedge Funds Drop The Ball On Medicines Company (MDCO)?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Medicines Company (MDCO)?

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Signal Says This Drug Stock Isn't Done Climbing
    Schaeffer's Investment Research

    Signal Says This Drug Stock Isn't Done Climbing

    The Medicines Company has nearly doubled in 2019